MetaCap

Outlook Therapeutics Inc. (OTLK)

NASDAQ: OTLKHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.39-0.011 (-2.74%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OTLK stock chart

Technical analysis

Key statistics

All statistics
Market cap
$94.94M
EPS (TTM)
-$0.70
52-week range
0.161 – 2.54
Day range
0.36 – 0.40
Volume / Avg
5.18M / 4.60M
Beta
—
Next earnings
Dec 18, 2026

52-week range

$0.161$2.54

OTLK stock today

Outlook Therapeutics (OTLK) closed at $0.39 on Nov 20, down 2.74% (-$0.011), versus the S&P 500's 3.70% decline. At this level, OTLK sits near the bottom of its 52-week range of $0.161 to $2.54: 84.6% below the high, set on Dec 17, 2025 and 142.2% above the low. OTLK is down 75.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 79.3%.

Outlook Therapeutics has posted a net loss over the last twelve months (EPS of -$0.70), so its P/E ratio is not meaningful. Outlook Therapeutics's next earnings report is expected on Dec 18, 2026.

Summary generated from market data by MetaCap's automated system. Methodology

About Outlook Therapeutics

Company profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Robert Charles Jahr
Headquarters
Iselin, NJ
Employees
17
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Outlook Therapeutics generated $1.4 million in revenue. Outlook Therapeutics reported a net loss of $62.4 million, compared with a loss of $75.4 million a year earlier. Gross margin was 4.0% and operating margin -4744.3%.

Outlook Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.41M————
Growth—————
Net income$-62.42M$-75.37M$-58.98M$-66.05M$-53.16M
EPS (diluted)$-1.79$-4.06$-4.72$-0.31$-0.35

Analyst forecast

Forecast

Consensus (4 analysts)

none

Avg. price target

$5.03+1189.74%

  • Strong buy 0
  • Buy 3
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $1.60High $10.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 18, 2026
EPS estimate
$-0.08
Last reported (Q3 2026)
Aug 12, 2026
EPS actual vs est.
$-0.15 vs —

OTLK news

All OTLK news

Outlook Therapeutics peers

Health Care sector
OTLK peer companies
CompanyPrice% ChgMarket capCompare
VYGRVoyager Therapeutics Inc.1.53-4.97%$95.21Mvs OTLK
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs OTLK
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs OTLK
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs OTLK
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs OTLK
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs OTLK
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs OTLK
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs OTLK

Indexes, lists and sector

Outlook Therapeutics stock FAQ

What is Outlook Therapeutics's stock price today?

OTLK last traded at $0.39 as of Nov 20, 4:00 PM EST, down 2.74% on the day. Prices are delayed at least 15 minutes.

Does Outlook Therapeutics pay a dividend?

No. Outlook Therapeutics does not currently pay a regular cash dividend.

When is Outlook Therapeutics's next earnings date?

Outlook Therapeutics is expected to report earnings on Friday, December 18, 2026. Analysts expect EPS of $-0.08.

Who is Outlook Therapeutics's CEO?

Mr. Robert Charles Jahr is the chief executive officer of Outlook Therapeutics Inc., which has about 17 employees.

Has OTLK ever split its stock?

Yes. The most recent OTLK stock split was a 1-for-20 split on Mar 14, 2024, one of 2 splits on record.

What is the OTLK 52-week high?

The 52-week high for OTLK is $2.54 and the 52-week low is $0.161. The stock is currently 84.6% below its high.

Compare OTLK